Skip to main content
. 2022 Feb 3;71(3):281–287. doi: 10.1538/expanim.21-0186

Fig. 4.

Fig. 4.

a Serum concentration of syndecan-1. b Serum concentration of TNFα. SHAM, no shock; HS, hemorrhagic shock; HS+DEX, hemorrhagic shock with dexmedetomidine; HS+DEX/MLA, hemorrhagic shock with dexmedetomidine and methyllycaconitine citrate; HS+MLA, hemorrhagic shock with methyllycaconitine citrate; TNF-α, tumor necrosis factor-alpha. aP<0.01 vs. SHAM. bP<0.01 vs. HS+DEX.